In Latvia, a 71-year-old pensioner died a few days after vaccination from the coronavirus of the Vaccine of the British-Swedish company Astrazeneca. This is reported by TASS with reference to the local television channel LTV7.
Latvian Health Inspection began investigating the happening.
Rigan Oleg Zeiggermeter received the first dose of the drug Astrazeneca party ABV5300 on March 5. The use of this party in early March was suspended several European Union countries, including Latvia. After the vaccination, the man appeared symptoms of light cold, on March 9, he died from eights of the lungs as a result of bilateral pneumonia.
“In principle, there is a question – on the one hand, we have a doctor from resuscitation, and the ambulance doctor called the thing connected with blood closures. We read in newspapers that in Austria, in Germany, Astrazeneca causes clomes”, – He told the TV channel of his son Pavel Zeighercher.
A representative of the State Medicine Agency and the European Medicine Agency in Latvia Zane Nikena stated that in Latvia there is not a single case of thrombosis that can be associated with vaccination. According to her, there is already a conclusion, according to which Astrazeneca vaccine is not related to the formation of thromboms. ” “It is not provided that you need to do tests before vaccination, there is also no information that vaccination could increase infection. After the first dose, it is possible to get sick if a person has already been infected and did not know about it,” she concluded.
Total in Latvia died six people who were vaccinated from coronavirus, also aware of 735 cases of side effects after vaccination.
On March 30, the Astrazeneca vaccine was renamed in Vaxzevria. A number of European countries have suspended or banned vaccination with the drug after discovery of thrombosis in the vaccinated patients. At the same time, the creators of the drug insist on its safety. The company stressed that the study of health over 17 million after vaccination showed the absence of increased risk of pulmonary artery embolism, deep veins thrombosis or thrombocytopenia.